Introduction
Attention investors and industry insiders! The Swedish private equity giant, EQT, is gearing up to launch the highly anticipated IPO of its dermatology unit, Galderma. This move is expected to raise a whopping €3 billion and shake up the world of pharmaceuticals as we know it. As one of the most significant developments in recent years, we have decided to break down everything you need to know about this latest move from EQT. So buckle up and get ready for an exciting ride into the future of healthcare investments!
What is Galderma?
Galderma is a global pharmaceutical company specializing in the research, development, and commercialization of dermatological treatments. The company was founded in 1981 as a joint venture between Nestlé and L’Oréal, and today it operates in over 100 countries with a team of more than 3,500 employees.
Galderma’s portfolio includes products for the treatment of acne, rosacea, skin cancer, psoriasis, atopic dermatitis, and other conditions. The company’s flagship product is Differin Gel 0.1%, which is approved for the treatment of acne in more than 60 countries. Other notable products include Oracea Capsules (for rosacea), Mirvaso Gel (for rosacea), Soolantra Cream (for rosacea), Cetaphil Restoraderm Skin Restoring Moisturizer (for eczema), Loceryl Nail Lacquer (for nail fungus), and Pliaglis Topical Anesthetic Cream (for procedural pain).
Galderma has a strong research and development pipeline with several potential blockbuster drugs in clinical trials. These include Actikerall (for actinic keratosis), Elevenate (for alopecia areata), Nemolizumab (for atopic dermatitis), and SAR439954 (for psoriasis). Galderma is also working on new formulations of existing products, such as a once-daily topical retinoid for
What is EQT?
EQT is a Swedish private equity firm that focuses on investments in companies with the potential for long-term growth. The firm has been active in the healthcare sector for many years and has a strong track record of successful investments in the space.
EQT’s latest move is to target €1 billion from the IPO of Galderma, a leading global pharmaceutical company specializing in dermatology. EQT first invested in Galderma in 2010, and the company has since grown significantly under EQT’s ownership. With an experienced management team in place, EQT believes that now is the right time to take Galderma public and maximize value for shareholders.
EQT’s IPO of Galderma is expected to be one of the largest European healthcare IPOs in recent years, and will provide significant returns for EQT’s investors.
The Galderma IPO
EQT, a Swedish private equity firm, is targeting €1 billion from the IPO of Galderma, a global pharmaceutical company specializing in skin health. This would be one of the largest IPOs in Europe this year and comes as EQT looks to cash out of its investment in Galderma.
EQT first acquired a stake in Galderma in 2011 from Nestle for €3.3 billion. Since then, EQT has invested an additional €1.5 billion into the company through a series of debt and equity financing rounds. These investments have helped fuel Galderma’s growth, particularly in China where it has become a leading player in the skincare market.
Now, EQT is looking to capitalize on this growth by taking Galderma public through an IPO on the Nasdaq Stockholm exchange. The IPO is expected to value Galderma at around €10 billion and will see EQT selling a 20-25% stake in the company.
This move by EQT comes as no surprise given that it has been increasingly active in the public markets in recent years. In 2017, EQT raised €4.75 billion through the sale of shares in H&M, the Swedish fashion retailer, and Zalando, the German online fashion retailer. And last year, EQT sold its stakes in TeliaSonera, the Finnish telecom operator, and virutal reality startup Oculus VR to Facebook for a combined €15 billion
EQT’s Previous Investments
EQT, a Swedish private equity firm, is targeting €1 billion from the IPO of Galderma, a French skincare company. This is EQT’s first move since it acquired a majority stake in Galderma from Nestle in 2014.
EQT has a long history of successful investments in Europe and North America. Some of its previous investments include:
– A minority stake in H&M, a Swedish fashion retailer
– A majority stake in IKEA, a Swedish home furnishings company
– A minority stake in Volvo Cars, a Swedish automaker
EQT’s track record of investing in successful companies gives it an edge when it comes to the Galderma IPO. Investors can be confident that EQT knows how to grow businesses and generate returns.
What Does This Mean for the Future of Galderma?
The private equity firm EQT is planning to raise €1 billion through an initial public offering (IPO) of its stake in Galderma, a Swiss-based global pharmaceutical company specializing in dermatology. This move comes as EQT looks to cash in on the success of Galderma’s recent performance and expand its portfolio beyond its current holdings.
If successful, the EQT IPO would value Galderma at €10 billion and would represent one of the largest ever exits for a private equity-backed company in Europe. It would also mark a significant milestone for EQT, which has been seeking to list its shares on the stock exchange for some time now.
The planned IPO is part of a broader strategy by EQT to divest itself of non-core assets and focus on core investments. In addition to Galderma, EQT also plans to sell its stakes in Swedish utility Vattenfall and Finnish forest company UPM-Kymmene. The proceeds from these sales will be used to pay down debt and fund future investments.
The timing of the EQT IPO is subject to market conditions but is expected to occur sometime before the end of 2018. If successful, it would provide a boost to the Swedish private equity firm’s profile and position it as one of the leading players in the European market.
Conclusion
EQT’s upcoming IPO of their dermatological business, Galderma, promises to be a lucrative move for the private equity firm. With an anticipated €3 billion in proceeds from the sale, EQT will have more capital to continue investing in companies that are poised for further growth and success. As investors look forward to learning more about what this latest development could mean for them and EQT as a whole, we anticipate exciting news on the horizon regarding their continued progress in the marketplace.
